ArticleInternal medicine (Tokyo, Japan)2021
Predictive Factors for Pneumomediastinum During Management of Connective Tissue Disease-related Interstitial Lung Disease: A Retrospective Study.
Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Spontaneous Pneumomediastinum in Rheumatoid Arthritis Associated Interstitial Lung Disease and Bronchiectasis: A Three-Component Pathophysiologic Framework.European journal of case reports in internal medicine · 2026Article
- Spectrum of autoantibodies and other serological parameters in connective tissue disease-associated interstitial lung disease patients.Frontiers in medicine · 2026Article
- Spontaneous pneumomediastinum and/or pneumothorax in anti-MDA5 dermatomyositis: a refined staging system.Respiratory research · 2025Article
- Article
- Article
- Case Report: Pneumomediastinum and pulmonary embolism in a 19-year-old with focal segmental glomerulosclerosis: a rare double-complication of corticosteroid therapy.Frontiers in cardiovascular medicine · 2025Article
- Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease.PloS one · 2025Article
- Tension Pneumomediastinum in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2024Review
- Pneumomediastinum and pneumothorax in coronavirus disease-2019: Description of a case series and a matched cohort study.Heliyon · 2024Article
- The characteristics of chest HRCT and pulmonary function tests in lung-onset primary sjogren's syndrome.Immunity, inflammation and disease · 2023Article
- Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: Time to nip them in the bud.Frontiers in immunology · 2022Review
- Pulmonary air leak syndrome in rheumatoid arthritis patient.SAGE open medical case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective To identify factors associated with pneumomediastinum during management of connective tissue disease (CTD)-related interstitial lung disease (ILD). Methods Patients diagnosed with pneumomediastinum after the initiation of corticosteroid therapy for their CTD-ILD were enrolled. The baseline characteristics of patients who developed pneumomediastinum after the initiation of corticosteroid therapy (n=13, all occurring within 120 days) were compared to those of patients who did not develop pneumomediastinum (n=49). A multivariate logistic regression analysis was performed to identify factors associated with pneumomediastinum. A receiver operating characteristic (ROC) curve analysis was also performed to assess the predictive performance. Results The body mass index (BMI) [odds ratio (OR) (95% confidence interval (CI)) 0.482 (0.272-0.853)] and serum lactate dehydrogenase (LDH) [OR (95% CI) 1.013 (1-1.025)] levels at baseline were identified as independent factors associated with pneumomediastinum after corticosteroid initiation. The optimal cut-off points of the BMI and LDH levels for predicting pneumomediastinum development, as estimated by the Youden index, were 20.2 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.